GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

Rating:
Buy ACOR
up 27.52 %

Acorda Therapeutics, Inc. (ACOR) rated Buy by FTN Equity Capital

Posted on: Thursday,  Mar 12, 2009  9:25 AM ET by FTN Equity Capital

FTN Equity Capital rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 03/12/2009, when the stock price was $24.85.
Since then, Acorda Therapeutics, Inc. has gained 27.53% as of 01/26/2016's recent price of $31.69.
If you would have followed this FTN Equity Capital 's recommendation on ACOR, you would have gained 27.52% of your investment in 2511 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Having access to accurate and timely information is essential for success in today's marketplace. At FTN Equity Capital Markets, our focus is on providing thorough and objective research to our clients, empowering them to make the well-informed and educated decisions that help enhance their investment process. Our highly experienced team of analytical experts research, examine, and evaluate businesses in several markets, including consumer, health care, business and technology services, and financial service sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2009 9:25 AM Buy
None
24.85
as of 12/31/2009
1 Week down  -7.20 %
1 Month down  -0.45 %
3 Months up  2.96 %
1 YTD down  -3.54 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy